Skip to main content
. Author manuscript; available in PMC: 2010 Aug 1.
Published in final edited form as: Nucl Med Biol. 2009 Aug;36(6):659–669. doi: 10.1016/j.nucmedbio.2009.04.003

Figure 4.

Figure 4

(A) Percentage of athymic rats with MCF7/HER2-18 breast carcinoma carcinomatous meningitis surviving after intrathecal administration of 46 or 92 µCi 211At-labeled trastuzumab, or saline 3 days after intrathecal injection of 5 × 106 tumor cells. (B) Percentage of animals having evidence of tumor in sections of the neuroaxis after treatment, as determined by histopathologial analysis. Location of sections as indicated in Figure 1, bottom.